Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing DPYD and UGT1A1 Screening to Guide Chemotherapy Dosing

Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing DPYD and UGT1A1 Screening to Guide Chemotherapy Dosing

BackgroundFluoropyrimidines (fluorouracil [5-FU], capecitabine) and irinotecan are commonly prescribed chemotherapy agents for gastrointestinal (GI) malignancies. Pharmacogenetic (PGx) testing for germline DPYD and UGT1A1 variants associated with reduced enzyme activity holds the potential to identi...

Full description

Bibliographic Details
Main Authors: Lisa A. Varughese, Madhuri Bhupathiraju, Glenda Hoffecker, Shannon Terek, Margaret Harr, Hakon Hakonarson, Christine Cambareri, Jessica Marini, Jeffrey Landgraf, Jinbo Chen, Genevieve Kanter, Kelsey S. Lau-Min, Ryan C. Massa, Nevena Damjanov, Nandi J. Reddy, Randall A. Oyer, Ursina R. Teitelbaum, Sony Tuteja
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Oncology
Subjects:
pharmacogenetics
cancer
DPYD
UGT1A1
chemotherapy
toxicity
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.859846/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.859846/full

Similar Items